Information Provided By:
Fly News Breaks for July 23, 2015
CSII
Jul 23, 2015 | 07:43 EDT
Leerink analyst Danielle Antalffy says the CMS Medicare Evidence Development & Coverage Advisory Committee panel on peripheral arterial disease removes a near-term overhang on shares of Cardiovascular Systems. The company should return to 20%-plus growth with both outpatient reimbursement and CMS panel risk now addressed, Antalffy tells investors in a research note. She keeps an Outperform rating on the stock with a $45 price target.
News For CSII From the Last 2 Days
There are no results for your query CSII